SOURCE: Generex Biotechnology

January 30, 2007 07:30 ET

Generex Biotechnology Exhibits at Arab Health 2007

TORONTO -- (MARKET WIRE) -- January 30, 2007 -- Generex Biotechnology Corporation (NASDAQ: GNBT) announced today that it is exhibiting at Arab Health 2007 at the Dubai International Exhibition Centre, Dubai, United Arab Emirates, January 29 - February 1, 2007 (www.arabhealthonline.com).

Arab Health is the largest healthcare exhibition in the Middle East, with a 31-year history of offering companies the opportunity to showcase their products and services in one of the fastest growing and most lucrative healthcare markets in the world.

There are more than 19 million adults with diabetes in the Eastern Mediterranean and Middle East Region, a prevalence of 7% (International Diabetes Federation, 2003).

The Generex exhibit features Generex Oral-lyn™, the Company's proprietary oral insulin spray product, and Glucose RapidSpray™, the Company's proprietary oral glucose spray product. The Company's product pipeline has received considerable interest from the region, and Generex is presently sourcing and evaluating prospective arrangements for the fast track registration, marketing, distribution and sale of its products in the region.

About Generex

Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. The Company's flagship product, oral insulin (Generex Oral-lyn™), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. For more information, visit the Generex website at www.generex.com.

Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Contact Information

  • For more information, please contact:

    For Generex:
    Shayne Gilliatt of Generex
    800-391-6755 or 416-364-2551

    Andrew Hellman of CEOcast, Inc.
    212-732-4300

    Michael Smith of Rubenstein Public Relations
    212-843-1900
    Email Contact